72 related articles for article (PubMed ID: 16146902)
1. Eptifibatide does not influence lymphocyte activation and CRP levels in patients with undergoing coronary angioplasty.
Finkelstein A; Izraelov S; Roth A; Ben-Shmuel S; Keren G; Miller H; George J
Int J Cardiovasc Intervent; 2004; 6(3-4):107-9. PubMed ID: 16146902
[TBL] [Abstract][Full Text] [Related]
2. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
Saltzman AJ; Mehran R; Hooper WC; Moses JW; Weisz G; Collins MB; Lansky AJ; Kreps EM; Leon MB; Stone GW; Dangas G
J Invasive Cardiol; 2010 Jan; 22(1):2-6. PubMed ID: 20048389
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
[TBL] [Abstract][Full Text] [Related]
4. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
Dery JP; Campbell ME; Mathias J; Pieper KS; Harrington RA; Madan M; Gibson CM; Tolleson TR; O'Shea JC; Tcheng JE;
Catheter Cardiovasc Interv; 2007 Jul; 70(1):43-50. PubMed ID: 17203469
[TBL] [Abstract][Full Text] [Related]
5. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
Am Heart J; 2003 Feb; 145(2):e6. PubMed ID: 12595861
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
Hobbach HP; Schuster P
Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
[TBL] [Abstract][Full Text] [Related]
7. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Gurbel PA; Bliden KP; Zaman KA; Yoho JA; Hayes KM; Tantry US
Circulation; 2005 Mar; 111(9):1153-9. PubMed ID: 15738352
[TBL] [Abstract][Full Text] [Related]
8. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
Galli M; Maggioni AP; Vassanelli C; Tavazzi L
Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
[TBL] [Abstract][Full Text] [Related]
9. Present and evolving role of eptifibatide in the treatment of acute coronary syndromes.
Tricoci P; Newby LK; Kandzari DE; Harrington RA
Expert Rev Cardiovasc Ther; 2007 May; 5(3):401-12. PubMed ID: 17489665
[TBL] [Abstract][Full Text] [Related]
10. Platelet aggregation inhibition blocks C-reactive protein and interleukin-6 (IL-6) elevation after the coronary angioplasty: effect of the -174 G/C IL-6 gene polymorphism.
Merino A; Gayá A; Segura I; Calvo J; Imízcoz C; Berenguel A; Alegría E
Am J Cardiol; 2004 Nov; 94(10):1300-3. PubMed ID: 15541252
[TBL] [Abstract][Full Text] [Related]
11. L-arginine attenuates lymphocyte activation and anti-oxidized LDL antibody levels in patients undergoing angioplasty.
George J; Shmuel SB; Roth A; Herz I; Izraelov S; Deutsch V; Keren G; Miller H
Atherosclerosis; 2004 Jun; 174(2):323-7. PubMed ID: 15136062
[TBL] [Abstract][Full Text] [Related]
12. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).
Tricoci P; Peterson ED; Chen AY; Newby LK; Harrington RA; Greenbaum AB; Cannon CP; Gibson CM; Hoekstra JW; Pollack CV; Ohman EM; Gibler WB; Roe MT
Am J Cardiol; 2007 May; 99(10):1389-93. PubMed ID: 17493466
[TBL] [Abstract][Full Text] [Related]
13. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.
Puma JA; Banko LT; Pieper KS; Sacchi TJ; O'Shea JC; Dery JP; Tcheng JE
J Am Coll Cardiol; 2006 Feb; 47(4):715-8. PubMed ID: 16487833
[TBL] [Abstract][Full Text] [Related]
15. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
16. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
17. Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial.
Labinaz M; Kaul P; Harrington RA; Chang WC; Kleiman NS; Simoons ML; Boersma E; Akkerhuis KM; Califf RM; Armstrong PW;
Can J Cardiol; 2004 Jun; 20(8):773-8. PubMed ID: 15229770
[TBL] [Abstract][Full Text] [Related]
18. Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy).
Teirstein PS; Kao J; Watkins M; Tannenbaum MA; Laufer N; Chang M; Mehran R; Dangas G; Russell ME; Ellis SG; Stone GW
Am J Cardiol; 2005 Aug; 96(4):500-5. PubMed ID: 16098300
[TBL] [Abstract][Full Text] [Related]
19. Optimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study.
Mardikar HM; Hiremath MS; Moliterno DJ; Mathew R; Arora R; Deo D; Hiremath JS; Deshpande NV; Khan A; Joseph J; Mukherjee D
Am Heart J; 2007 Aug; 154(2):344.e1-5. PubMed ID: 17643586
[TBL] [Abstract][Full Text] [Related]
20. GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention.
Welt FG; Rogers SD; Zhang X; Ehlers R; Chen Z; Nannizzi-Alaimo L; Phillips DR; Simon DI
Catheter Cardiovasc Interv; 2004 Feb; 61(2):185-9. PubMed ID: 14755809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
